Clinical trial designs incorporating predictive biomarkers.

Item

http://www.wikidata.org/entity/Q36534713

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical trial designs incorporating predictive biomarkers.

@ast

Clinical trial designs incorporating predictive biomarkers.

@en

type

Item

label

Clinical trial designs incorporating predictive biomarkers.

@ast

Clinical trial designs incorporating predictive biomarkers.

@en

prefLabel

Clinical trial designs incorporating predictive biomarkers.

@ast

Clinical trial designs incorporating predictive biomarkers.

@en

P1476

Clinical trial designs incorporating predictive biomarkers

@en

P2093

Daniel J Sargent

http://www.w3.org/2001/XMLSchema#string

Lindsay A Renfro

http://www.w3.org/2001/XMLSchema#string

Ming-Wen An

http://www.w3.org/2001/XMLSchema#string

Sumithra J Mandrekar

http://www.w3.org/2001/XMLSchema#string

P2860

An overview of the design and conduct of the BATTLE trials

Biomarkers, subgroup evaluation, and clinical trial design

Cetuximab for the treatment of colorectal cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Clinical trial designs for predictive marker validation in cancer treatment trials

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

P304

74-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CTRV.2015.12.008

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Himel Mallick

P577

2016-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289490567

http://www.w3.org/2001/XMLSchema#string

P698

26827695

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

4737867

http://www.w3.org/2001/XMLSchema#string